Pfizer will release its fourth-quarter earnings next month, and analysts anticipate a low double-digit profit dip.

Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Pfizer generated free cash flow of $10.4 billion in the 12 months ending Sept. 30, 2025. During this period, the pharma giant ...

Moderately bullish activity in Pfizer (PFE), with shares up 28c, or 1.1%, near $25.18. Options volume relatively light with 102k contracts traded ...

In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both numbers came in well above expectations, with diluted EPS $0.20 higher than ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

Pfizer shares have emerged as a compelling contrarian investment opportunity as the pharmaceutical giant trades at historically attractive valuations following an extended period of market skepticism.

After reporting record revenue a few years ago, Pfizer has faced tougher times in recent quarters. Challenges include a decline in demand for coronavirus products and patent expirations on the horizon ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

Shares of Pfizer Inc. PFE advanced 1.03% to $25.43 Tuesday, on what proved to be an all-around favorable trading session for ...

Pfizer propels itself into the obesity-drug game with $4.9 billion deal to buy Metsera. Shares of Metsera Inc. were rocketing into record territory in early Monday trading after the developer of ...